医学
荟萃分析
内科学
置信区间
随机对照试验
科克伦图书馆
败血症
相对风险
白细胞
临床试验
外科
作者
Yujiao Wu,Jing Zhang,Lijun Qi
出处
期刊:PubMed
[National Institutes of Health]
日期:2020-06-01
卷期号:32 (6): 691-695
被引量:7
标识
DOI:10.3760/cma.j.cn121430-20200427-00475
摘要
OBJECTIVE: To evaluate the efficacy and safety of Xuebijing injection for treating sepsis by systematic review. METHODS: Randomized controlled trials (RCT) of relevant Xuebijing injection for sepsis were searched in PubMed, Cochrane Library, CNKI, Wanfang database, VIP database from January 2000 to July 2019. Patients in control group were given conventional treatment, while patients in experimental group were treated with Xuebijing injection combined with conventional treatment. The qualities of the included trials were evaluated according to the Cochrane bias risk assessment tool. Meta-analysis of 28-day mortality, acute physiology and chronic health evaluation II (APACHE II), white blood cell count (WBC), C-reactive protein (CRP) and safety for sepsis patients with Xuebijing injection were conducted by RevMan 5.3 software. And the funnel chart was used to evaluate the publication bias of 28-day mortality. RESULTS: = 99%]. None of the 14 literatures reported the safety of Xuebijing injection, and there were no reports of participants' withdrawnness in halfway. Funnel chart analysis showed that there was a publication bias among studies with 28-day mortality. CONCLUSIONS: Xuebijing injection can improve the clinical symptoms, significantly reduce the mortality, and has high clinical application value.
科研通智能强力驱动
Strongly Powered by AbleSci AI